[A20-35] Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Last updated 01.10.2020
Commission awarded on 31.03.2020 by the Federal Joint Committee (G-BA).
Adults with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies
In case of 2 prior regimens: hint of greater harm due to side effects. In case of more than 2 prior therapies, due to major survival advantage and analogue side effects: hint of minor added benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A19-85||Trifluridine/tipiracil (gastric cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A16-54||Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A20-72||Trifluridine/tipiracil (colorectal cancer) - Addendum to Commission A20-35||Commission completed|